{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:25:30Z","timestamp":1779272730715,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00280-017-3395-5","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T08:50:50Z","timestamp":1500454250000},"page":"555-561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers"],"prefix":"10.1007","volume":"80","author":[{"given":"Tomoyuki","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morikazu","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Suguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Moriiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Soyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Sasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"issue":"3","key":"3395_CR1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13539-012-0064-8","volume":"3","author":"TS Solheim","year":"2012","unstructured":"Solheim TS, Fayers PM, Fladvad T, Tan B, Skorpen F, Fearon K, Baracos VE, Klepstad P, Strasser F, Kaasa S, European Palliative Care Research Collaborative (EPCRC) and the European Pharmacogenetic Study (EPOS) (2012) Is there a genetic cause of appetite loss?-an explorative study in 1853 cancer patients. J Cachexia Sarcopenia Muscle 3(3):191\u2013198","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"8","key":"3395_CR2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/oxfordjournals.aje.a009520","volume":"147","author":"RN Baumgartner","year":"1998","unstructured":"Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147(8):755\u2013763","journal-title":"Am J Epidemiol"},{"key":"3395_CR3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB, Nishijima TF (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58\u201367","journal-title":"Eur J Cancer"},{"issue":"3","key":"3395_CR4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s10120-015-0554-4","volume":"19","author":"T Sato","year":"2016","unstructured":"Sato T, Aoyama T, Hayashi T, Segami K, Kawabe T, Fujikawa H, Yamada T, Yamamoto N, Oshima T, Rino Y, Masuda M, Ogata T, Cho H, Yoshikawa T (2016) Impact of preoperative hand grip strength on morbidity following gastric cancer surgery. Gastric Cancer 19(3):1008\u20131015","journal-title":"Gastric Cancer"},{"issue":"12","key":"3395_CR5","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1245\/s10434-016-5360-7","volume":"23","author":"S Chemama","year":"2016","unstructured":"Chemama S, Bayar MA, Lanoy E, Ammari S, Stoclin A, Go\u00e9r\u00e9 D, Elias D, Raynard B, Antoun S (2016) Sarcopenia is associated with chemotherapy toxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol 23(12):3891\u20133898","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"3395_CR6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00520-014-2418-6","volume":"23","author":"HW Jung","year":"2015","unstructured":"Jung HW, Kim JW, Kim JY, Kim SW, Yang HK, Lee JW, Lee KW, Kim DW, Kang SB, Kim KI, Kim CH, Kim JH (2015) Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer 23(3):687\u2013694","journal-title":"Support Care Cancer"},{"issue":"4","key":"3395_CR7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jcsm.12107","volume":"7","author":"IJ Rutten","year":"2016","unstructured":"Rutten IJ, van Dijk DP, Kruitwagen RF, Beets-Tan RG, Olde Damink SW, van Gorp T (2016) Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle 7(4):458\u2013466","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"3395_CR8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ygyno.2016.05.027","volume":"142","author":"A Kumar","year":"2016","unstructured":"Kumar A, Moynagh MR, Multinu F, Cliby WA, McGree ME, Weaver AL, Young PM, Bakkum-Gamez JN, Langstraat CL, Dowdy SC, Jatoi A, Mariani A (2016) Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol 142(2):311\u2013316","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3395_CR9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2015.11.011","volume":"140","author":"JR Brewer","year":"2016","unstructured":"Brewer JR, Morrison G, Dolan ME, Fleming GF (2016) Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol 140(1):176\u2013183","journal-title":"Gynecol Oncol"},{"issue":"16","key":"3395_CR10","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.ejca.2010.06.124","volume":"46","author":"G Bolis","year":"2010","unstructured":"Bolis G, Scarfone G, Raspagliesi F, Mangili G, Danese S, Scollo P, Lo Russo D, Villa A, Aimone PD, Scambia G (2010) Paclitaxel\/carboplatin versus topotecan\/paclitaxel\/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer 46(16):2905\u20132912","journal-title":"Eur J Cancer"},{"issue":"4","key":"3395_CR11","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","volume":"15","author":"S Pignata","year":"2014","unstructured":"Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F, Multicentre Italian Trials in Ovarian cancer (MITO-7).; Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens et du sein (GINECO).; Mario Negri Gynecologic Oncology (MaNGO).; European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10).; Gynecologic Cancer InterGroup (GCIG) Investigators (2014) Carboplatin plus paclitaxel once a week versus every 3\u00a0weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15(4):396\u2013405","journal-title":"Lancet Oncol"},{"issue":"9698","key":"3395_CR12","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K, Japanese Gynecologic Oncology Group (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3\u00a0weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331\u20131338","journal-title":"Lancet"},{"issue":"22","key":"3395_CR13","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","volume":"96","author":"PA Vasey","year":"2004","unstructured":"Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, Scottish Gynaecological Cancer Trials Group (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96(22):1682\u20131691","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"3395_CR14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00223-014-9926-8","volume":"96","author":"MN Meriggioli","year":"2015","unstructured":"Meriggioli MN, Roubenoff R (2015) Prospect for pharmacological therapies to treat skeletal muscle dysfunction. Calcif Tissue Int 96(3):234\u2013242","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"3395_CR15","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s00198-012-2236-y","volume":"24","author":"A Mithal","year":"2013","unstructured":"Mithal A, Bonjour JP, Boonen S, Burckhardt P, Degens H, El Hajj Fuleihan G, Josse R, Lips P, Morales Torres J, Rizzoli R, Yoshimura N, Wahl DA, Cooper C, Dawson-Hughes B, IOF CSA Nutrition Working Group (2013) Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int 24(5):1555\u20131566","journal-title":"Osteoporos Int"},{"issue":"10","key":"3395_CR16","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2012.144","volume":"106","author":"CM Prado","year":"2012","unstructured":"Prado CM, Bekaii-Saab T, Doyle LA, Shrestha S, Ghosh S, Baracos VE, Sawyer MB (2012) Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer 106(10):1583\u20131586","journal-title":"Br J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3395-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3395-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3395-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T08:50:21Z","timestamp":1503910221000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3395-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["3395"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3395-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]}}}